Senators call for scrutiny of Walgreens-Rite Aid deal

Go back to Senators call for scrutiny of Walgreens-Rite Aid deal

Leerink Partners Would Buy CVS Health (CVS) on Current Weakness

October 30, 2015 1:39 PM EDT

Leerink Partners reiterated an Outperform rating and $125.00 price target on CVS Health (NYSE: CVS) following the company's 3Q earnings and conference call. Management highlighted that the core business continues to grow at a healthy rate. While 2016E EPS guidance is below consensus expectations, management reiterated that their longterm adjusted EPS growth... More